REATA PHARMACEUTICALS INC
Healthcare · Pharmaceutical Preparations · DE · SEC filings ↗ · Compare ⊕
Financials
SEC XBRL · annual| FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | |
|---|---|---|---|---|---|---|
| Revenue | $2.2M | $11.5M | $9.0M | $26.5M | $53.6M | $48.1M |
| Operating income | — | — | — | — | — | — |
| Net income | −$311.9M | −$297.4M | −$247.8M | −$290.2M | −$80.5M | −$47.7M |
| Total assets | $514.5M | $735.0M | $857.6M | $682.4M | $345.2M | $135.3M |
| Total liabilities | — | — | — | — | — | — |
| Equity | −$65.7M | $186.0M | $417.4M | $256.9M | $15.2M | −$147.0M |
| EPS (diluted) | $-8.54 | $-8.19 | $-7.35 | $-9.54 | $-2.91 | $-1.99 |
| Shares out. | 36.5M | 36.3M | 33.7M | 30.4M | 27.7M | 23.9M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2022- Operating margin
- —
- Net margin
- −14075.0%
- Return on equity
- 474.8%
- Return on assets
- −60.6%
- Return on capital (ROCE)
- —
- Liabilities / assets
- —
- Debt / equity
- —
- Book value / share
- $-1.80
- Revenue growth (YoY)
- −80.7%
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2022- Accruals / assets
- −20.9%clean
- Piotroski F-Score
- 1/7weak
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.
Signs
● 1 severe● 3 warning● 2 good- Negative shareholder equity
- Reported a net loss
- Revenue declined year-over-year
- Negative operating cash flow
- Strong return on equity (>15%)
- Clean earnings (low accruals)
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Material events
SEC Form 8-K · most recent- Terminated a material agreement · Completed an acquisition or disposition · Delisting / listing-standard notice · Modified shareholder rights · Change in control · Director / officer change · Amended charter or bylawsSep 26, 2023
- Shareholder vote · Other material eventSep 21, 2023
- Other material eventSep 12, 2023
- Entered a material agreement · Other material eventJul 31, 2023
- Other material eventJul 28, 2023
- Entered a material agreementJul 11, 2023
- Entered a material agreementJun 20, 2023
- Shareholder voteJun 7, 2023
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗- 15-12GOct 6, 2023
- SC 13D/ASep 28, 2023
- 4Sep 28, 2023
- SC 13D/ASep 28, 2023
- 4Sep 26, 2023
- 8-KSep 26, 2023
- SC 13D/ASep 26, 2023
- 4FORM 4 SUBMISSIONSep 26, 2023
- 4FORM 4 SUBMISSIONSep 26, 2023
- 4FORM 4 SUBMISSIONSep 26, 2023
- 4FORM 4 SUBMISSIONSep 26, 2023
- 4FORM 4 SUBMISSIONSep 26, 2023
- 4FORM 4 SUBMISSIONSep 26, 2023
- 4FORM 4 SUBMISSIONSep 26, 2023
- 4FORM 4 SUBMISSIONSep 26, 2023
Event-driven situations (1)
Spot an error in this record? Report it. Every correction is verified against the source filing before we change anything.